The inhibition of noscapine to CYP3A4 and CYP2C9: explanation for clinical DDI between noscapine and warfarin

被引：0
|
作者：
Fang, Zhong-Ze [1 ]
Yang, Ling [1 ]
机构：
[1] Chinese Acad Sci, Dalian Inst Chem Phys, Lab Pharmaceut Resource Discovery, Dalian 116023, Peoples R China
来源：
DRUG METABOLISM REVIEWS | 2009年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
150
引用
收藏
页码：74 / 74
页数：1
相关论文
共 50 条
  • [31] In Vitro Human Cytochrome P450 Isozymes (CYPs) Inhibition of Epifriedelanol on CYP2C9, CYP2E1 and CYP3A4
    Yu, Jie
    Zou, Fengxian
    Zhao, Lifang
    LATIN AMERICAN JOURNAL OF PHARMACY, 2022, 41 (08): : 1677 - 1683
  • [32] A study on the relationship between warfarin dose and CYP2C9 polymorphism
    Yeneka, LA
    Hung, A
    Gaffney, D
    CLINICA CHIMICA ACTA, 2005, 355 : S388 - S388
  • [33] Kinetic analysis of fluvastatin metabolism by CYP2C9 and its allelic variants, CYP2C9*2 and CYP2C9*3
    Einolf, HJ
    Fischer, V
    DRUG METABOLISM REVIEWS, 2003, 35 : 191 - 191
  • [34] Association between CYP2C9 genetic polymorphism and warfarin treatment
    Ardicoglu, NY
    Tunca, A
    Adam, B
    Kargyly, A
    Koksal, V
    Karanfil, A
    CLINICA CHIMICA ACTA, 2005, 355 : S166 - S166
  • [35] Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5′-hydroxylation
    Iida, I
    Miyata, A
    Arai, M
    Hirota, M
    Akimoto, M
    Higuchi, S
    Kobayashi, K
    Chiba, K
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (01) : 7 - 9
  • [36] CYP3A4, CYP3A5 and CYP2C9 are responsible for the N-demethylation of meperidtne to normeperidine in vitro.
    Santucci, R
    Innocenti, F
    Ramirez, J
    House, L
    Ratain, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P79 - P79
  • [37] Influence of the CYP2C9*3 allele on the pharmacological interaction between warfarin and simvastatin
    Botton, Mariana Rodrigues
    Hutz, Mara Helena
    Suarez-Kurtz, Guilherme
    PHARMACOGENOMICS, 2012, 13 (14) : 1557 - 1559
  • [38] Effect of myricetin on cytochrome P450 isoforms CYP1A2, CYP2C9 and CYP3A4 in rats
    Guo, Yu-Jin
    Zheng, Shuang-li
    PHARMAZIE, 2014, 69 (04): : 306 - 310
  • [39] Effects of CYP2C9*3,*28 and*30 on CYP2C9 inhibition profiles and glyburide metabolism in vitro
    Maekawa, Keiko
    Harakawa, Noriko
    Kim, Su-Ryang
    Sawada, Jun-ichi
    Saito, Yoshiro
    DRUG METABOLISM REVIEWS, 2011, 43 : 61 - 61
  • [40] SIMULTANEOUS EVALUATION OF CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP1A2 HYDROXYLATION CAPACITY IN HUMANS
    De Andres, F.
    Paulmichl, M.
    Llerena, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S61 - S61
12345